Entering text into the input field will update the search result below

NantKwest in Pact with Generate Life’s CBR on potential COVID-19 treatment

Aug. 10, 2020 1:50 PM ETImmunityBio, Inc. (IBRX) StockIBRXBy: Vandana Singh, SA News Editor3 Comments
  • Cord Blood Registry (CBR) by Generate Life Sciences and NantKwest (NK +6.7%) announces collaboration for development of COVID-19 treatment leveraging newborn stem cells.
  • CBR will provide research-donated umbilical cord tissue-derived mesenchymal stem cells
  • Patient trials expected to begin in the fall, and both companies anticipate an FDA-approved treatment to be in the market for use in Covid-19 patients by early 2021.

Recommended For You

About IBRX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
IBRX--
ImmunityBio, Inc.